Clear Cell Renal Cell Carcinoma

Oncology·MeSH: Carcinoma

Prevalence

48.0 / 100K

Incidence

15.0 / 100K/yr

18 drugs in development·10 companies·18 clinical trials

Drug Pipeline by Phase

Phase 3(8)

Drug	Company
cabozantinib	GH Research PLC (GHRS)
Cabozantinib	Arcus Biosciences, Inc. (RCUS)
Casdatifan	Arcus Biosciences, Inc. (RCUS)
Casdatifan	ASTRAZENECA PLC (AZN)
casdatifan (AB521)	Arcus Biosciences, Inc. (RCUS)
clostridium butyricum cbm 588 probiotic strain	GH Research PLC (GHRS)
lenvatinib	GH Research PLC (GHRS)
Sturlimogene Erparepvec	Replimune Group, Inc. (REPL)

Phase 2(5)

Drug	Company
ALLO-316	Allogene Therapeutics, Inc. (ALLO)
ALLO-647	Allogene Therapeutics, Inc. (ALLO)
Cyclophophamide	Allogene Therapeutics, Inc. (ALLO)
Fludarabine	Allogene Therapeutics, Inc. (ALLO)
Tivozanib	Replimune Group, Inc. (REPL)

Phase 1(4)

Drug	Company
AB521	EXELIXIS, INC. (EXEL)
ARO-HIF2	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CTX131	CRISPR Therapeutics AG (CRSP)
XmAb819	Xencor Inc (XNCR)

Preclinical(1)

Drug	Company
oncr-021	Oncorus, Inc. (ONCR)

BioSniper tracks 18 drugs in development for Clear Cell Renal Cell Carcinoma across 10 companies.

There are 18 clinical trials targeting Clear Cell Renal Cell Carcinoma tracked by BioSniper.

The estimated prevalence of Clear Cell Renal Cell Carcinoma is approximately 48.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.